Mycophenolate Mofetil Accord (Mycophenolate Mofetil)

The drug is a pro‑drug that is converted to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanosine nucleotides needed for T‑ and B‑cell proliferation, thereby reducing immune responses that can damage transplanted tissue or cause autoimmune inflammation.

The appropriate dose of Mycophenolate Mofetil Accord is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Mycophenolate Mofetil is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil targets a different metabolic pathway (IMPDH) and is often used in combination regimens. It offers a distinct side‑effect profile, with less nephrotoxicity but a higher risk of bone‑marrow suppression and gastrointestinal upset.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Mycophenolate Mofetil Accord is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule should follow the healthcare professional’s instructions.

The most serious risks include severe infections due to immune suppression, bone‑marrow suppression leading to low blood cell counts, and rare but potentially fatal complications such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored closely for signs of these conditions.

Mycophenolate Mofetil should not be used by pregnant women, individuals with known hypersensitivity to the drug, or patients with uncontrolled infections. It is also contraindicated in patients with severe hepatic impairment unless specifically advised by a specialist.